Altimmune, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Altimmune, Inc. is a biopharmaceutical company in the late clinical stage, dedicated to developing innovative peptide-based therapies for liver and cardiometabolic conditions. The company's main therapeutic candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing evaluation for several indications, including obesity, metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). Regarding pemvidutide's progress, the IMPACT Phase 2b MASH trial has completed enrollment, with 24-week data already published in The Lancet and 48-week data anticipated by the end of 2025. An End-of-Phase 2 meeting with the FDA is scheduled for late 2025, with plans to initiate Phase 3 trials in 2026. Pemvidutide has received Fast Track designation from the U.S. FDA for MASH and AUD. Furthermore, Phase 2 trials for AUD (RECLAIM study) and ALD (RESTORE study) are actively enrolling or have completed enrollment. Previously, Altimmune was developing HepTcell, an immunotherapeutic for chronic hepatitis B. However, the company discontinued its development in March 2024 following Phase 2 trial results that were deemed insufficient to warrant further advancement. The company focuses entirely on advancing pemvidutide through clinical development. Altimmune, Inc. maintains its headquarters in Gaithersburg, Maryland.
Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?
Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Altimmune Sets Pemvidutide's Phase 3 MASH Playbook as AUD Data Near
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup
ALT and the Rise of Dual Agonists Targeting Liver Disease
Is Altimmune Worth Buying Ahead of 2026 Catalysts?
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
Altimmune to Participate in Upcoming Investor Conferences
New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026
FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
Here's Why You Should Add Altimmune Stock to Your Portfolio Now
Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil
Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript
Altimmune Q1 Earnings Call Highlights
Altimmune Announces First Quarter 2026 Financial Results and Business Update
Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026